Infectious Disease Clinics of North America (INFECT DIS CLIN N AM )

Publisher: Elsevier

Description

Each issue of Infectious Disease Clinics reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.

Impact factor 2.31

  • Hide impact factor history
     
    Impact factor
  • 5-year impact
    2.81
  • Cited half-life
    7.70
  • Immediacy index
    0.67
  • Eigenfactor
    0.00
  • Article influence
    0.99
  • Website
    Infectious Disease Clinics website
  • Other titles
    Infectious disease clinics of North America, Infectious disease clinics
  • ISSN
    0891-5520
  • OCLC
    14781687
  • Material type
    Periodical, Internet resource
  • Document type
    Journal / Magazine / Newspaper, Internet Resource

Publisher details

Elsevier

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Pre-print allowed on any website or open access repository
    • Voluntary deposit by author of authors post-print allowed on authors' personal website, arXiv.org or institutions open scholarly website including Institutional Repository, without embargo, where there is not a policy or mandate
    • Deposit due to Funding Body, Institutional and Governmental policy or mandate only allowed where separate agreement between repository and the publisher exists.
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months .
    • Set statement to accompany deposit
    • Published source must be acknowledged
    • Must link to journal home page or articles' DOI
    • Publisher's version/PDF cannot be used
    • Articles in some journals can be made Open Access on payment of additional charge
    • NIH Authors articles will be submitted to PubMed Central after 12 months
    • Publisher last contacted on 18/10/2013
  • Classification
    ​ green

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Condoms remain the most effective barrier against the sexual transmission of the human immunodeficiency virus (HIV). Male condoms have proven to be 80% to 90% effective, and female condoms have similar results. Poor adherence and improper use limit their effectiveness. In addition to condoms, microbicides are a promising barrier against HIV transmission. More than 50 candidate topical microbicide compounds have undergone preclinical or clinical testing in the last 10 years, but there are currently no US Food and Drug Administration (FDA)-approved compounds. Rectal microbicides are also being developed, as anal receptive sex is an effective mode of HIV transmission. Copyright © 2014 Elsevier Inc. All rights reserved.
    Infectious Disease Clinics of North America 12/2014; 28(4):585-599.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The reproductive health needs of all women of childbearing age should routinely address effective and appropriate contraception, safer sex practices, and elimination of alcohol, illicit drugs and tobacco should pregnancy occur. Combined antepartum, intrapartum, and infant antiretroviral (ARV) prophylaxis are recommended because ARV drugs reduce perinatal transmission by several mechanisms, including lowering maternal viral load and providing infant pre- and post-exposure prophylaxis. Scheduled cesarean delivery at 38 weeks with IV AZT decreases the risk of perinatal transmission if the HIV RNA is greater than 1000 copies/mL or if HIV levels are unknown near the time of delivery. Oral AZT should generally be given for at least 6 weeks to all infants perinatally exposed to HIV to reduce perinatal transmission of HIV. Copyright © 2014 Elsevier Inc. All rights reserved.
    Infectious Disease Clinics of North America 12/2014; 28(4):529-547.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although some success was achieved in recent years in HIV prevention, an effective vaccine remains the means with the most potential of curtailing HIV-1 infections worldwide. Despite multiple failed attempts, a recent HIV vaccine regimen demonstrated modest protection from infection. Although the protective efficacy in this trial was not sufficient to warrant licensure, it spurred renewed optimism in the field and has provided valuable insights for improving future vaccine designs. This review summarizes the pertinent details of vaccine development and discusses ways the field is moving forward to develop a vaccine to prevent HIV infection and disease progression.
    Infectious Disease Clinics of North America 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Remarkable advances have been made in the treatment of human immunodeficiency virus (HIV)-1 infection, but in the entire history of the epidemic, only 1 patient has been cured. Herein we review the fundamental mechanisms that render HIV-1 infection difficult to cure and then discuss recent clinical and experimental situations in which some form of cure has been achieved. Finally, we consider approaches that are currently being taken to develop a general cure for HIV-1 infection.
    Infectious Disease Clinics of North America 09/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: In HIV-infected individuals, coinfection with HBV and/or HCV is common because of shared modes of transmission. It is known that HIV accelerates progression of liver disease and results in increased morbidity and mortality associated with viral hepatitis, but it is less clear if viral hepatitis has a direct effect on HIV. Treatment of viral hepatitis improves outcomes and should be considered in all HIV-infected patients. Treatment of HBV without concurrent treatment of HIV is risky because resistance can occur in both viruses if regimens are not carefully chosen.
    Infectious Disease Clinics of North America 09/2014; 28(3):477-499.
  • Infectious Disease Clinics of North America 09/2014; 28(3):xiii-xiv.
  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV testing and incidence are stable, but trends for certain populations are concerning. Primary prevention must be reinvigorated and target vulnerable populations. Science and policy have progressed to improve the accuracy, speed, privacy, and affordability of HIV testing. More potent and much better tolerated HIV treatments and a multidisciplinary approach to care have increased adherence and viral suppression. Changes to health care law in the United States seek to expand the affordability and access of improved HIV diagnostics and treatment. Continued challenges include improving long-term outcomes in people on lifetime regimens, reducing comorbidities associated with those regimens, and preventing further transmission.
    Infectious Disease Clinics of North America 09/2014; 28(3):339-353.
  • Article: HIV/AIDS.
    Infectious Disease Clinics of North America 09/2014; 28(3):xv-xvi.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite enormous improvements in effectiveness of treatment for HIV infection, opportunistic infections continue to occur in those who have not yet been diagnosed with HIV and in those who are not receiving antiretroviral therapy. This review focuses on tuberculosis and cryptococcal infections, the most common opportunistic infections (OIs) in patients living with human immunodeficiency virus infection around the world, as well as on new developments in progressive multifocal leukoencephalopathy and pneumocystis pneumonia. In the sections on these conditions, updates on diagnosis, treatment, and complications, as well as information on when to start antiretroviral therapy is provided. The article concludes with a discussion of new data on 2 vaccine-preventable OIs, human papillomavirus and varicella-zoster virus.
    Infectious Disease Clinics of North America 09/2014; 28(3):501-518.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The number of persons living with HIV worldwide reached approximately 35.3 million in 2012. Meanwhile, AIDS-related deaths and new HIV infections have declined. Much of the increase in HIV prevalence is from rapidly increasing numbers of people on antiretroviral treatment who are now living longer. There is regional variation in epidemiologic patterns, major modes of HIV transmission, and HIV program response. It is important to focus on HIV incidence, rather than prevalence, to provide information about HIV transmission patterns and populations at risk. Expanding HIV treatment will function as a preventive measure through decreasing horizontal and vertical transmission of HIV.
    Infectious Disease Clinics of North America 09/2014; 28(3):323-337.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this article, we review the options for initial antiretroviral therapy, including the data from clinical trials to support these choices and the factors to consider in selection of a regimen to best fit each patient.
    Infectious Disease Clinics of North America 09/2014; 28(3):421-438.
  • Conference Paper: Mycoplasma Genitalium
    National STD Prevention Conference 2014 Centers for Disease Control and Prevention; 06/2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Emerging evidence suggests that antimicrobial prescribing behaviors are influenced by local culture and a prescribing etiquette that is abided by all health care professionals. Local cultural unspoken rules often play a more pivotal role than the recommendations of guidelines and policies drawn up by experts in influencing antimicrobial prescribing. It is important to recognize the key drivers of prescribing behaviors and the incentives to alter behaviors and to incorporate these into stewardship programs. This review summarizes key concepts in behavior change in antimicrobial prescribing and the gaps that exist in addressing behavior change in this field.
    Infectious Disease Clinics of North America 06/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The successful integration of technology in antimicrobial stewardship programs has made it possible for clinicians to function more efficiently. With government endorsement of electronic health records (EHRs), EHRs and clinical decision support systems (CDSSs) are being used as decision support tools to aid clinicians in efforts to improve antibiotic use. Likewise, medical applications (apps) have provided educational tools easily accessible to clinicians through their mobile devices. In this article, the impact that informatics and technology have had on promoting antibiotic stewardship is described, focusing on EHRs and CDSSs, apps, electronic resources, and social media.
    Infectious Disease Clinics of North America 06/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: One of the impediments to the success of antimicrobial stewardship is the lack of availability of rapid and sensitive laboratory tests. The last decade has seen an explosion in new technologies that permit, in less than 4 hours, the identification of organisms and their resistance markers. In addition, the use of biomarkers has been explored in algorithms to distinguish infections that require antimicrobial agents. Clinical microbiology laboratories also contribute to the success of stewardship programs through compilation of aggregate antimicrobial susceptibility data. This article reviews rapid diagnostics, the use of biomarkers, and antibiogram development to antimicrobial stewardship activities and the subsequent impact on patient outcomes.
    Infectious Disease Clinics of North America 06/2014;
  • Infectious Disease Clinics of North America 06/2013; 27(2):429–457.